Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

This study has been completed.
National Ataxia Foundation
Bob Allison Ataxia Research Center (BAARC)
Information provided by (Responsible Party):
Theresa Zesiewicz, University of South Florida Identifier:
First received: October 8, 2009
Last updated: June 15, 2012
Last verified: June 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)